Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa
Article Date
December 7, 2023
This article is featured on another website.
Go to article
July 8, 2025
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
July 8, 2025
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
June 24, 2025
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
June 24, 2025
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.